Business
NetworkNewsWire Announces Publication Discussing Biotech Advances in Cannabis Research
New York, New York--(Newsfile Corp. - November 16, 2017) - NetworkNewsWire ("NNW"), a mult...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Discussing Biotech Advances in Cannabis ResearchNew York, New York--(Newsfile Corp. - November 16, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, \"Biosynthesis: Making the Impossible Possible in Medicinal Cannabis,\" discusses the challenges facing cannabis researchers and the solutions available through biosynthesis of the more than 90+ cannabinoids found in the highly regulated plant.To view the full publication, visit: https://www.networknewswire.com/biosynthesis-making-impossible-possible-medicinal-cannabis/ \"InMed (IMLFF Profile) recently announced a provisional patent application filing for its proprietary cannabinoid manufacturing biosynthesis program - the first of many to come (http://nnw.fm/Z30dH). Once this inaugural patent application is converted into an international Patent Cooperation Treaty (PCT) application and is pursued on a global scale in important jurisdictions, InMed will have significant commercial protection for its biosynthesis program. The company plans to actively convert this initial patent filling and subsequent provisional patents into national-stage filings in all major commercial jurisdictions.\"'Importantly, this study offers further validation of InMed's capabilities in moving the science of cannabinoid pharmaceuticals forward,' InMed President and CEO Eric A. Adams said in the press release. 'Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.'\"This groundbreaking work is not only helping InMed toward overcoming drug approval barriers but could also have a huge impact on the efforts of other drug development companies within the cannabis sector that are striving to create cannabinoid-based therapies to treat various medical conditions.\"About InMedInMed is a preclinical stage biopharmaceutical com...